Plethora Solutions (United Kingdom)
The Company's principal product is a treatment remedy for male premature ejaculation which obtained marketing authorization from the European Commission. Although the European MAA has been authorized by the European Commission, information contained on this website is provided for business development and investor relations purposes only. Patients who suffer or believe they suffer from PE should contact their physician in the first instance.
Basic Information
- Category: business
- Website: http://www.plethorasolutions.co.uk/
Documented Facts
- Inception (Wikidata): 2003 (Source 2: Wikidata Q43895220, revision 2474142799)
- Country (Wikidata; date unspecified): United Kingdom (Source 2: Wikidata Q43895220, revision 2474142799; Source 3: Wikidata label: Q145, revision 2554939741)
- Official website (Wikidata; date unspecified): http://www.plethorasolutions.co.uk/ (Source 2: Wikidata Q43895220, revision 2474142799)
Evidence and Sources
- Plethora Solutions (United Kingdom) — Official Website (official)
- Wikidata Q43895220, revision 2474142799 (knowledge-base)
- Wikidata label: Q145, revision 2554939741 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Plethora Solutions (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/plethora-solutions-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/plethora-solutions-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/plethora-solutions-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
The Company's principal product is a treatment remedy for male premature ejaculation which obtained marketing authorization from the European Commission. Although the European MAA has been authorized by the European Commission, information contained on this website is provided for business development and investor relations purposes only. Patients who suffer or believe they suffer from PE should contact their physician in the first instance.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.